

#23

DATE: December 21, 2001 SHEET _1_ of _5_

Form PTO - 1449 (Modified)

| | | | |
|---|--|-----------------------------------|--------------------------|
| FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE | | ATTY. DOCKET NO. 40015630-0004 | SERIAL NO. 09/481,207 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | APPLICANT J. Phillips | |
| (Use several sheets if necessary) (37 CFR 1.98 (b)) | | FILING DATE January 11, 2000 | GROUP 1625 |

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | PATENT NUMBER | ISSUE DATE | PATENTEE | CLASS | SUB CLASS | FILING DATE |
|---|---------------|---------------|----------------------------|------------------|--------------|----------------|
| Citation Reviewed | 334. | 5 2 4 4 6 7 0 | 09/14/93 | Upson, et al. | | |
| | 335. | 5 1 2 4 1 5 8 | 06/23/92 | Ruwart, et al. | | |
| | 336. | 5 2 8 8 5 0 6 | 02/22/94 | Spickett, et al. | | |
| | 337. | 5 7 9 8 1 2 0 | 08/25/98 | Tomohisa, et al. | | |
| | 338. | 5 8 7 9 7 0 8 | 03/09/99 | Makino, et al. | | |
| | 339. | 5 9 7 2 3 8 9 | 10/26/99 | Shell, et al. | | |
| | 340. | 6 1 4 7 1 0 3 | 11/14/00 | Anousis, et al. | | |
| | 341. | 6 1 3 6 3 4 4 | 10/24/00 | Depui, et al. | | |
| | 342. | 6 1 6 6 2 1 3 | 12/26/00 | Anousis, et al. | | |
| | 343. | 6 1 8 3 7 7 6 | 02/06/01 | Depui, et al. | | |
| | 344. | 6 1 4 3 7 7 1 | 11/07/00 | Lindberg, et al. | | |
| | 345. | 6 2 8 4 2 7 1 | 09/04/01 | Lundberg, et al. | | |
| | 346. | 6 2 7 4 1 7 3 | 08/14/01 | Sachs, et al. | | |
| EXAMINER Jane T. Fan | | | DATE CONSIDERED 1/31/02 | | | |
| EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | |

(Form PTO-1449)

Form PTO - 1449 (Modified)

| | | |
|---|-----------------------------------|--------------------------|
| FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE | ATTY. DOCKET NO. 40015630-0004 | SERIAL NO. 09/481,207 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | APPLICANT J. Phillips | |
| (Use several sheets if necessary) (37 CFR 1.98 (b)) | FILING DATE January 11, 2000 | GROUP 1625 |

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

| EXAMINER INITIAL | DOCUMENT NUMBER | PUBLIC- ATION DATE | COUNTRY OR PATENT OFFICE | CLASS | SUB CLASS | TRANS- LATION | |
|---|-----------------|------------------------------|---------------------------------|-------------|------------------|------------------|----|
| | | | | | | YES | NO |
| g.b | 347. | 0 3 1 6 3 0 1 8 | 11/20/90 | JP | | | |
| | 348. | 6 2 2 8 3 9 6 4 | 12/09/87 | JP | | | |
| | 349. | 9 6 0 1 6 2 3 | 01/25/96 | WO A1 | | | |
| | 350. | 9 6 0 1 6 2 4 | 01/25/96 | WO A1 | | | |
| | 351. | 9 6 0 2 2 3 6 | 02/01/96 | WO A1 | | | |
| | 352. | 9 6 2 4 3 3 8 | 08/15/96 | WO A1 | | | |
| | 353. | 9 7 2 5 0 6 5 | 07/17/97 | WO A1 | | | |
| | 354. | 9 8 0 0 1 1 4 | 01/08/98 | WO A2 | | | |
| | 355. | 9 9 2 5 3 2 3 | 05/27/99 | WO A1 | | | |
| | 356. | 9 9 5 3 9 1 8 | 10/28/99 | WO A1 | | | |
| | 357. | 0 0 0 1 3 7 2 | 01/13/00 | WO A2 & A3 | | | |
| | 358. | 0 0 0 9 0 9 2 | 02/24/00 | WO A1 | | | |
| | 359. | 0 0 1 5 1 9 5 | 03/23/00 | WO A1 | | | |
| | 360. | 0 0 5 0 0 3 8 | 08/31/00 | WO A1 | | | |
| | 361. | 0 0 1 0 9 9 9 | 03/02/00 | WO A2 & A3 | | | |
| | 362. | 0 1 0 3 7 0 7 | 01/18/01 | WO A1 | | | |
| | 363. | 0 1 2 4 7 8 0 | 04/12/01 | WO A2 | | | |
| | 364. | 0 1 3 4 5 7 3 | 05/17/01 | WO A1 | | | |
| | 365. | 0 2 3 7 2 0 0 | 07/01/92 | EPO B1 | | | |
| | 366. | 0 2 4 8 6 3 4 | 07/21/93 | EPO A2 & B1 | | | |
| | 367. | 0 3 3 8 8 6 1 | 01/20/93 | EPO B1 | | | |
| | 368. | 0 6 5 4 4 7 1 | 05/24/95 | EPO A1 & B1 | | | |
| | 369. | 1 0 0 4 3 0 5 | 05/21/00 | EPO A1 | | | |
| | 370. | 9 6 1 1 2 3 8 | 08/21/96 | KR B1 | | | |
| | 371. | 9 6 1 1 3 9 0 | 08/22/96 | KR B1 | | | |
| u | 372. | 9 6 0 3 6 0 5 | 03/20/96 | KR B1 | | | |
| g.g | 373. | 2 0 2 4 9 9 3 | 12/31/90 | SP | | | |
| EXAMINER Jane T. Fan | | | DATE CONSIDERED 4/21/02 | | | | |
| EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | | |

(Form PTO-1449)

Form PTO - 1449 (Modified)

| | | |
|---|-----------------------------------|------------------------------|
| FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE | ATTY. DOCKET NO. 40015630-0004 | SERIAL NO. 09/481,201 207 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | APPLICANT J. Phillips | |
| (Use several sheets if necessary) (37 CFR 1.98 (b)) | FILING DATE January 11, 2000 | GROUP 1625 |

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

| | | |
|-----|------|--|
| 2-3 | 374. | Sharma, et al., "Oral Pharmacokinetics of Omeprazole and Lansoprazole After Single and Repeated Doses as Intact Capsules or As Suspensions in Sodium Bicarbonate", <u>Alimentary Pharmacology & Therapeutics</u> , Vol. 14, No. 7, pp. 887-892 (July 2000). |
| | 375. | McAndrews, et al., "Omeprazole and Lansoprazole Suspensions for Nasogastric Administration", <u>American Journal of Health-System Pharm.</u> , Vol. 56, pg. 81 (January 1, 1999). |
| | 376. | Hardy, et al., "Inhibition of Gastric Secretion by Omeprazole and Efficiency of Calcium Carbonate on the Control of Hyperphosphatemia in Patients on Chronic Hemodialysis", <u>Artificial Organs</u> , Vol. 22, No. 7, pp. 569-573 (July 1998). |
| | 377. | Schmassmann, et al., "Antacid Provides Better Restoration of Glandular Structures Within the Gastric Ulcer Scar Than Omeprazole", <u>Gut</u> , Vol. 35, No. 7, pp. 896-904 (July 1994). |
| | 378. | Di Iorio, et al., "Aluminum and Phosphorus Urinary Excretion After Modifying Gastric Acid Secretion In Chronic Renal Failure", <u>Trace Elements and Electrolytes</u> , Vol. 13, No. 2, pp. 96-101 (1996). |
| | 379. | Di Iorio, et al., "Aluminum and Phosphorus Urinary Excretion After Modifying Gastric Acid Secretion In Normal Subjects", <u>Trace Elements and Electrolytes</u> , Vol. 13, No. 1, pp. 47-49 (1996). |
| | 380. | Osler, et al., "Effect of Omeprazole On The Phosphate-Binding Capacity of Calcium Carbonate", <u>Nephron</u> , Vol. 69, pp. 89-90 (1995). |
| | 381. | Schmassmann, et al., "Antacids in Experimental Gastric Ulcer Healing: Pharmacokinetics of Aluminum and Quality of Healing", <u>European Journal of Gastroenterology & Hepatology</u> , Vol. 5, Suppl. 3, pp. S111-S116 (1993). |
| | 382. | Humphries, et al., "Review Article: Drug Interactions With Agents Used to Treat Acid-Related Diseases", <u>Alimentary Pharmacology & Therapeutics</u> , Vol. 13, Suppl. 3, pp. 18-26 (August 1999). |
| | 383. | Crill, et al., "Upper Gastrointestinal Tract Bleeding in Critically Ill Pediatric Patients", <u>Pharmacotherapy</u> , Vol. 19, No. 2, pp. 162-180 (February 1999). |
| | 384. | Vincent, et al., "Concurrent Administration of Omeprazole and Antacid Does Not Alter The Pharmacokinetics and Pharmacodynamics Of Dofetilide in Healthy Subjects", <u>Clinical Pharmacology & Therapeutics</u> , Vol. 59, No. 2 (P11-93), pg. 182 (February 1996). |
| | 385. | Ching, et al., "Antacids - Indications and Limitations", <u>Drugs</u> , Vol. 47, No. 2, pp. 305-317 (February 1994). |
| | 386. | Garnett, "Efficacy, Safety, and Cost Issues in Managing Patients With Gastroesophageal Reflux Disease", <u>Am. J. Hosp. Pharm.</u> , Vol. 50, No. 4 (Suppl. 1), pp. S11-18 (April 1993). |
| | 387. | Hixson, et al., "Current Trends in the Pharmacotherapy for Peptic Ulcer Disease", <u>Arch. Intern. Med.</u> , Vol. 152, No. 4, pp. 726-732 (April 1992). |
| | 388. | Hixson, et al., "Current Trends in the Pharmacotherapy for Gastroesophageal Reflux Disease", <u>Arch. Intern. Med.</u> , Vol. 152, No. 4, pp. 717-723 (April 1992). |
| | 389. | Maxwell, et al., "Control of Gastric pH In A Critical Care Unit: Physician Behavior and Pharmacologic Effectiveness", <u>Am. Rev. Respir. Dis.</u> , Vol. 143, No. 4 (Part 2), pg. A482 (1991). |
| | 390. | Siepler, et al., "Selecting Drug Therapy for Patients With Duodenal Ulcers", <u>Clinical Pharmacy</u> , Vol. 9, No. 6, pp. 463-467 (June 1990). |
| 2-3 | 391. | Rodrigo, et al., "Therapeutic Approach to Peptic Ulcer Relapse", <u>Methods Find Exp. Clinical Pharmacology</u> , Vol. 11 (Supp. 1), pp. 131-135 (1989). |

EXAMINER

Jane T. Fan

DATE CONSIDERED

1/31/02

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449)

Form PTO - 1449 (Modified)

| | | |
|---|-----------------------------------|------------------------------|
| FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE | ATTY. DOCKET NO. 40015630-0004 | SERIAL NO. 09/481,201 207 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | APPLICANT J. Phillips | |
| (Use several sheets if necessary) (37 CFR 1.98 (b)) | FILING DATE January 11, 2000 | GROUP 1625 |

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

| | | |
|-----|------|---|
| 8.3 | 392. | Deakin, et al., "Therapeutic Progress - Review XXXIII: Are We Making Progress In The Drug Treatment of Oesophageal Disease?", <u>Journal of Clinical Pharmacy and Therapeutics</u> , Vol. 13, No. 6, pp. 365-374 (December 1988). |
| | 393. | Walan, "Pharmacological Agents For Peptic Ulcer Disease", <u>Scand. J. Gastroenterol. Suppl.</u> , Vol. 19, No. 98, pg. 1 (1984). |
| | 394. | Al-Assi, et al., "Treatment of Helicobacter Pylori Infection With Omeprazole-Amoxicillin Combination Therapy Versus Ranitidine/Sodium Bicarbonate-Amoxicillin", <u>The American Journal of Gastroenterology</u> , Vol. 90, No. 9, pp. 1411-14 (September 1995). |
| | 395. | Tanaka, et al., "Pathogenesis of The Earliest Epithelial Cell Damage Induced by Mepirazole and Cysteamine in the Rat Duodenum", <u>Japanese Journal of Pharmacology</u> , Vol. 51, No. 4, pp. 509-519 (December 1989). |
| | 396. | Yasuda, et al., "Antacids Have No Influence on the Pharmacokinetics of Rabeprazole, A New Proton Pump Inhibitor, In Healthy Volunteers", <u>International Journal of Clinical Pharmacology and Therapeutics</u> , Vol. 37, No. 5, pp. 249-253 (1999). |
| | 397. | Andersson, et al., "Pharmacokinetic Studies With Esomeprazole, the (S)-Isomer of Omeprazole", <u>Clinical Pharmacokinetics</u> , Vol. 40, No. 6, pp. 411-426 (2001). |
| | 398. | Maconi, et al., "Prolonging Proton Pump Inhibitor-Based Anti-Helicobacter Pylori Treatment From One to Two Weeks in Duodenal Ulcer: Is It Worthwhile?", <u>Digest Liver Disease</u> , Vol. 32, pp. 275-280 (May 2000). |
| | 399. | Doan, et al., "Comparative Pharmacokinetics and Pharmacodynamics of Lansoprazole Oral Capsules and Suspension in Healthy Subjects", <u>American Journal of Health-System Pharmacists</u> , Vol. 58, No. 16, pp. 1512-19 (August 15, 2001). |
| | 400. | Pilbrant, "Principles for Development of Antacids", <u>Scand. J. Gastroenterol Suppl.</u> , Vol. 75, pp. 32-36 (1982). |
| | 401. | DiGiacinto, et al., "Stability of Suspension Formulations of Lansoprazole and Omeprazole Stored in Amber-Colored Plastic Oral Syringes", <u>Annals of Pharmacotherapy</u> , Vol. 34, No. 5, pp. 600-605 (May 2000). |
| | 402. | Kromer, "Similarities and Differences in the Properties of Substituted Benzimidazoles: A Comparison Between Pantoprazole and Related Compounds", <u>Digestion</u> , Vol. 56, No. 6, pp. 443-454 (1995). |
| | 403. | Thomson, "Are The Orally Administered Proton Pump Inhibitors Equivalent? A Comparison of Lansoprazole, Omeprazole, Pantoprazole, and Rabeprazole", <u>Current Gastroenterology Reports</u> , Vol. 2, No. 6, pp. 482-493 (December 2000). |
| | 404. | Cederberg, et al., "Effect of Once Daily Intravenous and Oral Omeprazole on 24-Hour Intra-gastric Acidity in Healthy Subjects", <u>Scand. J. Gastroenterol.</u> , Vol. 28, No. 2, pp. 179-184 (February 1993). |
| | 405. | Sharma, et al., "The Pharmacodynamics of Lansoprazole Administered Via Gastrostomy as Intact, Non-Encapsulated Granules", <u>Alimentary Pharmacology Therapy</u> , Vol. 12, pp. 1171-1174 (1998). |
| 8.3 | 406. | Regardh, et al., "Pharmacokinetics and Metabolism of Omeprazole in Animals and Man - An Overview", <u>Scand. J. Gastroenterology</u> , Vol. 108, pp. 79-94 (1985). |

EXAMINER

Jane T. Fan

DATE CONSIDERED

1/31/01

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449)

Form PTO-1449 (Modified)

| | | |
|---|-----------------------------------|------------------------------|
| FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE | ATTY. DOCKET NO. 40015630-0004 | SERIAL NO. 207 09/481,201 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | APPLICANT J. Phillips | |
| (Use several sheets if necessary) (37 CFR 1.98 (b)) | FILING DATE January 11, 2000 | GROUP 1625 |

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

| | |
|------|---|
| 407. | Londong, et al., "Dose-Response Study of Omeprazole on Meal-Stimulated Gastric-Acid Secretion and Gastrin Release", <u>Gastroenterology</u> , Vol. 85, No. 6, pp. 1373-1378 (1983). |
| 408. | Howden, et al., "Oral Pharmacokinetics of Omeprazole", <u>European Journal of Clinical Pharmacology</u> , Vol. 26, pp. 641-643 (1984). |
| 409. | Prichard, et al., "Omeprazole: A Study of Its Inhibition of Gastric pH and Oral Pharmacokinetics After Morning or Evening Dosage", <u>Gastroenterology</u> , Vol. 88, Part 1, pp. 64-69 (1985). |
| 410. | Oosterhuis, et al. "Omeprazole: Pharmacology, Pharmacokinetics and Interactions", <u>Digestion</u> , Vol. 44, Suppl. 1, pp. 9-17 (1989). |
| 411. | Arvidsson, et al., "Peak Distortion in the Column Liquid Chromatographic Determination of Omeprazole Dissolved in Borax Buffer", <u>Journal of Chromatography</u> , Vol. 586, Part 2, pp. 271-276 (1991). |
| 412. | McAnderews, et al., "Alternative Method for Administering Proton-Pump Inhibitors Through Nasogastric Tubes", <u>American Journal of Health-System Pharmacy</u> , Vol. 56 (May 15, 1999). |
| 413. | Poster presentation presented in January 1994 by J. Phillips and M. Metzler at the Society for Critical Care Medicine Annual Meeting relating to SOS. |
| 414. | University of Missouri Surgical Society Scientific Program presented by J. Phillips entitled "Stress-Related Mucosal Damage Optimizing Drug Therapy in the 1990's" (June 1994). |
| 415. | Presentation by J. Phillips entitled "Update on Acid-Related Disorders - Optimizing Pharmacotherapy for the 1990's" (1996). |
| 416. | Presentation by J. Phillips entitled "Stress-Related Mucosal Damage - Optimizing Drug Therapy" (1997). |
| 417. | Presentation by J. Phillips entitled "Overview of Omeprazole Suspension - From Efficacy to Effectiveness Alternative Dosing of PPI's" (August 1998). |
| 418. | Presentation by J. Phillips entitled "Simplified Omeprazole Suspension (SOS) (1998). |
| 419. | Presentation by J. Phillips entitled "Advances in the Use of PPI's From Efficacy to Effectiveness" (1999). |
| 420. | Presentation by J. Phillips entitled "Overview of Omeprazole Suspension - Problems With Administering Granules" (1999/2000). |
| 421. | Presentation on Overview of Omeprazole Suspension entitled "Pharmacotherapy Related Outcomes Group Researching Effective Stress Ulcer Strategies" (2000). |
| 422. | Presentation on Overview of Omeprazole Suspension entitled "Stress Ulcer Prophylaxis in the 21 st Century" (2001). |

EXAMINER

Jane T. Fan

DATE CONSIDERED

1/31/02

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449)